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Gorlin syndrome is a typical
case of debated hypersensi-
tivity to radiation, although it
is well-recognized as a
cancer-prone disorder. The
present data reveal that only
Gorlin cells presenting se-
vere deficiency in PTCH1
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https://doi.org/10.1016/j.ijrobp.2018.05.057Purpose: Gorlin syndrome (or basal-cell nevus syndrome) is a cancer-prone genetic
disease in which hypersusceptibility to secondary cancer and tissue reaction after
radiation therapy is debated, as is increased radiosensitivity at cellular level. Gorlin
syndrome results from heterozygous mutations in the PTCH1 gene for 60% of pa-
tients, and we therefore aimed to highlight correlations between intrinsic radiosen-
sitivity and PTCH1 gene expression in fibroblasts from adult patients with Gorlin
syndrome.
Methods and Materials: The radiosensitivity of fibroblasts from 6 patients with Gor-
lin syndrome was determined by cell-survival assay after high (0.5-3.5 Gy) and low
(50-250 mGy) g-ray doses. PTCH1 and DNA damage response gene expression
was characterized by real-time polymerase chain reaction and Western blotting.
DNA damage and repair were investigated by gH2AX and 53BP1 foci assay. PTCH1, Laboratory of Genomics
Cre´mieux, 91057, Evry,
m EURATOM (RISK-IR,
wradsensor).
be found at https://doi.org/
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had a direct role in regulating
intrinsic radiosensitivity after
both high and low radiation
doses. PATCHED1 level may
thus provide a prognostic
screen for radiosensitive pa-
tients with PTCH1 hetero-
zygous mutations.knockdownwas performed in cells from healthy donors by using stable RNA interfer-
ence. Gorlin cells were genotyped by 2 complementary sequencing methods.
Results: Only cells from patientswith Gorlin syndromewho presented severe deficiency
in PATCHED1 protein exhibited a significant increase in cellular radiosensitivity,
affecting cell responses to both high and low radiation doses. For 2 of the radiosensitive
cell strains, heterozygous mutations in the 5’ end of PTCH1 gene explain PATCHED1
protein deficiency. In all sensitive cells, DNA damage response pathways (ATM,
CHK2, and P53 levels and activation by phosphorylation) were deregulated after irradi-
ation, whereas DSB repair recognition was unimpaired. Furthermore, normal cells with
RNA interference-mediatedPTCH1 deficiency showed reduced survival after irradiation,
directly linking this gene to high- and low-dose radiosensitivity.
Conclusions: In the present study,we showan inverse correlation betweenPTCH1 expres-
sion level and cellular radiosensitivity, suggesting an explanation for the conflicting results
previously reported for Gorlin syndrome and possibly providing a basis for prognostic
screens for radiosensitive patients with Gorlin syndrome and PTCH1 mutations. 2018
The Author(s). Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
At least 15 different genetic disorders are now associated
with increased cellular radiosensitivity (1). Gorlin syndrome
is a typical case of debated cellular hypersensitivity, although
it is well-recognized as a cancer-prone disorder. Gorlin
syndrome is mainly caused by heterozygous mutations in the
PTCH1 gene, which codes for the Sonic hedgehog (SHH)
receptor (2, 3), because mutations in this gene have been
described in around 60% of patients with a Gorlin phenotype
(4, 5). We investigated the correlations between cellular
radiosensitivity and PTCH1 gene expression in fibroblasts
isolated from adult patients with Gorlin syndrome.
Gorlin syndrome, or basal cell nevus syndrome (BCNS),
is an autosomal dominant inherited disease with prevalence
varying from 1 in 57,000 to 1 in 256,000 and is characterized
by developmental abnormalities and a predisposition to skin
neoplasms and medulloblastoma, as reviewed by Lo Muzio
(6). Because PATCHED1 is a repressor of the SHH signaling
pathway through its interaction with the smoothened protein,
it has been proposed to act as a tumor suppressor. Conse-
quently mutations of the second allele of PTCH1 result in
tumor formation (7). To studymolecular events and basal cell
carcinoma (BCC) appearance associated with Ptch1 muta-
tions, several murine models with heterozygous mutations,
spontaneous or generated, have been described and are
reviewed by Saran and Nitzki et al (7, 8). In addition to
developmental pattern issues, individuals with Ptch1 muta-
tions originally showed spontaneous medulloblastomas (9)
and soft-tissue tumors such as rhabdomyosarcomas, with
an incidence depending on the genetic background (10).
After ionizing radiation (IR), Ptch1 heterozygous embryos
exhibit a higher frequency of IR-induced developmental
defects compared to their wild-type littermates (10), sug-
gesting that Ptch1þ/e mice are more sensitive to radiation.
Since then,Ptch1 knockoutmice have been usefulmodels for
molecular events involved in BCC development uponirradiation (11), as well as for adverse tissue reaction
occurrence, such as cataract (12).
The first evidence that IR dramatically increases the inci-
dence of tumors in patients with Gorlin syndrome was re-
ported more than 40 years ago in patients with cancer (13),
notably those treated for medulloblastoma, and this has since
been the focus of several case reports (14-17). In particular,
children with BCNS appear to be at high risk of developing
multiple BCCs in irradiated areas, usually from 6 months to
3 years after radiation therapy (13, 18). Consequently, mini-
mizing IR exposure and using nonionizing imaging modal-
ities when possible is recommended (19). However, this
susceptibility to IR-induced cancer is more controversial in
adults, and several authors have reported patients who did not
develop secondary BCC after multiple radiation therapy
treatments (20, 21). In addition, patients with Gorlin syn-
drome may be prone to tissue reactions after radiation ther-
apy, although this clinical aspect has been poorly
documented. At the cellular level, data are again inconsistent,
with some groups reporting decreased cell survival after ra-
diation exposure (22-24) and others not reporting this (25-27).
In the present study, we show that only Gorlin cells pre-
senting severe deficiency in PTCH1 gene and protein
expression exhibited a significant increase in radiosensitivity,
which suggests an explanation for the conflicting results so far
reported concerning the response to radiation in cells from
patients with Gorlin syndrome. Furthermore, our molecular
data provide evidence for a direct role of the PATCHED1
protein in the regulation of intrinsic radiosensitivity.
Methods and Materials
Cells from patients with Gorlin syndrome
Nonimmortalized dermal fibroblasts from 6 adult patients
with Gorlin syndrome (GM0-; age 27 to 58 years, 3 men
and 3 women; see details in Table E1; available online at
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from the Coriell Institute cell repositories (Camden, NJ).
Genotyping had not been performed, and clinical infor-
mation in the repository was limited to classification as
patients with BCNS. Primary dermal fibroblasts from 4
healthy individuals were used as control cells (human
normal fibroblast [HNF] 1-4), obtained either from the
Coriell Institute (1 donor) or in-house (3 different donors).
Cultures were performed in Dulbecco’s Modified Eagle
MediumdGlutamax medium (ThermoFisher Scientific,
Waltham, MA) supplemented with 15% fetal bovine serum
(ThermoFisher), between passages 6 to 10, with plating
density adapted to each cell strain (see details on prolifer-
ative capacity in Table E2; available online at https://doi.
org/10.1016/j.ijrobp.2018.05.057).
Radiation sensitivity
Cells were exposed to high (0.5-3.5 Gy; dose rate, 0.89 Gy/
min) and low IR doses (50-250 mGy; dose rate, 50 mGy/
min) using g-rays from a 137Cs source. For colony survival
assays, cells were exposed to IR 5 hours after seeding and
were cultured for 2 weeks. All colonies containing more
than 50 cells were scored as survivors.
Quantitative polymerase chain reaction
Total RNAwas isolated from fibroblasts at 80% confluence
with the RNeasy MiniKit (Qiagen, Hilden, Germany); an
equal amount of RNA was used for reverse transcription
(High-Capacity RNA-to-cDNA Kit, ThermoFisher). Real-
time polymerase chain reactions were carried out
using complementary DNA as template and were amplified
using iTaq Universal probes supermix (Biorad, Hercules,
CA) and specific probes to target the PTCH1 gene
(Hs00970977_m1; ThermoFisher). The 18S housekeeping
gene was used as internal control (Hs99999901_s1).
Western blot analysis
Fibroblasts were harvested at 80% by trypsinization.
Cell pellets were washed and resuspended in radio-
immunoprecipitation assay buffer (Sigma, St. Louis, MO)
for total protein extraction and sonicated for phosphoryla-
tion studies. Proteins were quantified using the Bradford
method, loaded on a 4% to 12% stain-free gel (Biorad) for
40 minutes to 1 hour at a constant 200V, and transferred
for 10 minutes at a constant 2.5 A in the Trans-Blot
Turbo Transfer System (Biorad). Membranes were blocked
in tris-buffered salineetween with 5% milk or bovine
serum albumin and immunoblotted overnight (L isoform
PATCHED1, epitope aa 1-50, Abcam; full antibody table in
Table E3; available online at https://doi.org/10.1016/j.
ijrobp.2018.05.057). Protein detection was performed
using the ChemiDoc MP system (Biorad), and normaliza-
tion was done with the stain-free system from Image Lab
software (Biorad).PTCH1 next-generation sequencing mutation
screening
PTCH1mutation screeningwas performed through 2 different
next-generation sequencing procedures: exonic pyrose-
quencing with the Roche GS Junior System at CEA-CNRGH
(Evry, France) for transcriptsNM_1083602 andNM_1083603
(PTCH1_M and L’ isoforms) and sequencing by synthesis
following coding sequence capture on an Illumina Miseq
benchtop sequencer (Illumina, SanDiego,CA) at theBergonie´
Institute (INSERM, Bordeaux, France) for transcript
NM_000264 (PTCH1_L isoform) (Methods E1; available
online at https://doi.org/10.1016/j.ijrobp.2018.05.057).
gH2AX and 53BP1 foci assays
For gH2AX (28), cells were irradiated with 3 Gy by using a
137Cs g-ray source (dose rate, 1.02 Gy/min1), further
cultured for the indicated times, fixed with 4% formaldehyde
(paraformaldehyde) and permeabilized with 0.2% Triton X-
100, followed by staining with 40-6-diamidino-2-
phenylindole dihydrochloride and gH2AX antibody. The
average number of separate gH2AX foci was assessed on at
least 300 cells using the Cellomics ArrayScan VTI (Ther-
moFisher). For 53BP1, cells were irradiated with 3 Gy by
using an x-ray source (XRAD 320; Precision X-Ray, North
Branford, CT), further cultured for the indicated times, fixed
on coverslips (3% paraformaldehyde, 2% sucrose phosphate-
buffered saline [PBS]) and permeabilized (20 mM HEPES
pH 7.4, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose and
0.5% Triton X-100). Coverslips were incubated with 5%
goat serum PBS for blocking, before immunostaining with
anti-53BP1 antibody in 2% goat serum PBS. Foci in 50 cells
were counted using an Eclipse Ti-E inverted microscope
(Nikon). (See Methods E4 for detailed foci assays; available
online at https://doi.org/10.1016/j.ijrobp.2018.05.057).
RNA interference
Fibroblasts from healthy donors were stably transduced with
lentiviral vectors (Vectalys SA., Toulouse, France). Trans-
ductions of sh-PTCH1-GFP and sh-scramble-GFP were
performed on fibroblasts at w40% confluence. Cells were
incubated for 6 hours with lentiviral particles (multiplicity of
infection at 20) in the presence of hexadimethrine bromide at
4 mg/mL (Sigma). After 3 days, transduced cells (efficiency
60%-98%) were sorted by flow cytometry (MoFlo; Beckman
Coulter, Brea, CA) according to green florescent protein
fluorescence and amplified for 1 week before analysis.
Statistics
The Student test was used. Significance was assessed ac-
cording to a normal distribution law, and means were
considered significantly different if Z0 > 1 [Z0Z (mean X
e mean Y)/N*(Os (mean X)2 þ s (mean Y)2] where
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Fig. 1. A subpopulation of highly PTCH1-deficient Gorlin cells is radiosensitive. (A) Colony survival assays showed that
GM0-1657, -1552, and -2138 cells exhibited significantly greater sensitivity to high doses than cells from 3 healthy donors
(HNF 1-3 in black, averaged); 6 Gorlin cell strains (GM0-) were studied in 3 independent experiments, each with 3 to 6
replicates. (B) Parameters of the survival curves. HNF: mean for cells from 3 healthy donors. GM0-: cells from Gorlin
patients. SF2 is the survival fraction after 2 Gy. D0 is the dose for which 37% survival was observed. (C) Colony survival
assays showed hypersensitivity after low radiation doses for GM0-1657, -1552, and -2138; (dose rate, 50 mGy/min; survival
values in Table E4; available online at https://doi.org/10.1016/j.ijrobp.2018.05.057); 3 independent experiments, each with 3
to 6 replicates. (D) PTCH1 mRNA levels (L isoform) measured in Gorlin cells by real-time quantitative polymerase chain
reaction on 3 replicates and compared with the mean value for 3 normal cells, normalized to 100. (E) Representative image of
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respectively.
Results
Cells from 3 patients with Gorlin syndrome are
radiosensitive
Colony survival assays showed that cells from only 3 pa-
tients with Gorlin syndrome (GM0-1657, -1552, and -2138)
out of the 6 cell strains examined exhibited significantly
greater sensitivity to medium and high doses (Fig. 1A and
B) than cells from 3 healthy donors (HNF 1-3). Similar data
were found after low doses (Fig. 1C and Table E4; available
online at https://doi.org/10.1016/j.ijrobp.2018.05.057),
within a window ranging from 50 to 250 mGy, suggesting a
low-dose hypersensitivity response. Although a tendency to
hypersensitivity between 100 and 250 mGy was observed
for all Gorlin cells, survival reduction was significant only
for the 3 cell strains sensitive to high doses (patients GM0-
1657, -1552, and -2138).
Marked PTCH1 gene expression deficiency
correlates with radiosensitivity
The radiosensitive cells (GM0-1657, -1552 and -2138)
exhibited significantly less PTCH1 messenger RNA
(mRNA) than cells from the 3 healthy donors (19%, 25%,
and 21%, respectively; n Z 6, P < .01) (Fig. 1D). Simi-
larly, in protein level, PATCHED1 expression was lower in
the radiosensitive cells (22%, 25%, and 39% respectively,
n Z 3, P < .01) (Fig. 1E). Hedgehog signaling was also
affected in these cells, notably with a reduced expression of
the GLI2 transcription factor (Fig. E1; available online at
https://doi.org/10.1016/j.ijrobp.2018.05.057).
Variable severity of PTCH1 mutations
Genetic studies (Table 1) revealed that cells from 5 pa-
tients with Gorlin syndrome exhibited at least 1 hetero-
zygous mutation in the PTCH1 gene, but with different
types and locations (Fig. 1F). Four of these mutations were
not previously reported. For GM0-1657 and GM0-2138,
the insertion and deletion events in exon 2 led to a pre-
mature stop codon in exon 3, which predicts nonsense-
mediated mRNA decay for the mutated transcript or a
strongly truncated protein that is probably rapidly
degraded. For GM0-1575, -1725, and -2098, the observedWestern blot analysis with PATCHED1 antibody (L isoform, epit
(GM0-), with vinculin as a loading control of total protein extr
image of PATCHED1 protein, with the 2 intracellular arms and t
NH2 terminal region is targeted in 2 radiosensitive cell strains. R
mutation found for each Gorlin cell line. Significant differencesmutations predicted more limited defects for the
PATCHED1 protein. For 1 patient (GM0-1552), a variant
was detected in the 50UTR region, common to GM0-1575,
1725, and 2098, but no mutation was found in the coding
regions of PTCH1.
Defective DNA damage response signaling in
radiosensitive Gorlin cells
For the ATM/CHK2/P53 pathway, downregulations of pro-
tein expression were found at a basal level in the radiosen-
sitive cells as compared to controls (Fig. E2; available online
at https://doi.org/10.1016/j.ijrobp.2018.05.057) and after
2 Gy irradiation (Fig. 2A). Furthermore, activation by irra-
diation was impaired, notably for phospho-CHK2 and
phospho-P53, and this deficiency was observed in all the
radiosensitive cells (Fig. 2B), which may be due both to the
reduced basal level and to an activation defect. For phospho-
ATM, only GM0-1657 and -1552 were affected.
To monitor DNA double-strand break formation and
repair, enumeration of gH2AX and 53BP1 foci was per-
formed at 0, 0.25, 2, 6, 24, and 48 hours after 3 Gy irra-
diation and showed no difference between normal and
Gorlin cells (Fig. 2C and D).
Induced PATCHED1 deficiency in normal cells
results in increased radiosensitivity
PTCH1 expression was decreased in cells from heathy
donors after infection with a lentiviral vector carrying a
short hairpin RNA (shRNA) sequence targeting PTCH1,
with a mean reduction of at least 60% for mRNA and
around 50% for the protein (Fig. 3A, 3B, and 3F). Colony
survival assays showed that cells from 3 different healthy
donors transduced with sh-PTCH1 lentivector showed a
significantly smaller survival fraction at 2 Gy, whereas cells
receiving a scramble sh vector did not differ from controls
(Fig. 3C and Fig. E3; available online at https://doi.org/10.
1016/j.ijrobp.2018.05.057). Furthermore, irradiation be-
tween 0.5 and 3.5 Gy resulted in a survival curve close to
that of the radiosensitive cells from patients with Gorlin
syndrome (Fig. 3D). Moreover, induced PATCHED1 defi-
ciency in cells from heathy donors resulted in increased
sensitivity to low doses of IR (100 and 200 mGy, Fig. 3E
and Fig. E4; available online at https://doi.org/10.1016/j.
ijrobp.2018.05.057). Knock-down cells also showed de-
fects in DNA damage response (DDR) pathways and
notably decreased basal expression of CHK2 and P53
(Fig. 3F).ope aa 1-50) on normal fibroblasts (HNF-) and Gorlin cells
acts. (F) Localization of PTCH1 mutations on a schematic
he 2 large extracellular loops required for HH binding. The
ed beads represent the putative amino-acid modified by the
: * at P < .05 and ** at P < .01.
Table 1 Genotyping analysis by next-generation sequencing
Cell strain Localization hg 19 Mutations and variants References
GM0-2098 Chr9: 98221881 Intron 17
Chr9: 98270646 50UTR
isoform L
Splice site mutation (donor
site þ1) C>G
Insertion T>TGCC
Exon 18 skipping and stop
codon in exon 19
Triplet insertion
Unpublished
Tietze 2013 (37)
GM0-1725 Chr9: 98268700 Exon 2
Chr9: 98270646 50UTR
isoform L
Missense mutation
(c383T > L128P)
Insertion: T>TGCC
Protein structure modification
Triplet insertion
Unpublished
Tietze 2013 (37)
GM0-1575 Chr9: 98218697 Intron 18
Chr9: 98270646 50UTR
isoform L
Splice site mutation (acceptor
site -2) T>G
Insertion: T>TGCC
Exon 19 skipping and stop
codon in exon 20
Triplet insertion
Unpublished
Tietze 2013 (37)
GM0-2138 Chr9: 98268800 Exon 2 Insertion (c.283 C>CT ) Frameshift and stop codon in
exon 3
Boutet 2003 (38)
Chidambaram 1996 (39)
GM0-1552 Chr9: 98270646 50UTR
isoform L
Insertion T>TGCC Triplet insertion Tietze 2013 (37)
GM0-1657 Chr9: 98268792 Exon 2
Chr9: 98211572 Exon 22
Chr9: 98209213 Exon 23
Deletion GT>G
Missense mutation
(T4093A > T1364S)
Missense mutation
(C4325T > R1442Q)
Frameshift and stop codon in
exon 3
Protein sequence
modification
Protein sequence
modification
Chidambaram 1996 (39)
Boutet 2003 (38)
Unpublished
Five Gorlin cell strains harbor specific heterozygous mutation(s) in the PTCH1 gene, notably 2 splice site, 3 missense, and 2 frameshift mutations. Cells
from 2 Gorlin patients (GM0-1657, -2138) present nonsynonymous mutations at the 50 end of the PTCH1 gene that predict higher protein deficiency as
compared to the other cell strains. For 1 patient (GM0-1552), a variant was found in the 50UTR region, which is common to GM0-1575, 1725, and 2098,
but no mutations were detected in the coding regions of PTCH1. Locations are indicated using the human genome reference hg19.
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The radiosensitivity of patients affected by Gorlin syn-
drome is currently debated. The present study, designed to
investigate correlations between cellular radiosensitivity
and PTCH1 expression in the cells of patients with Gorlin
syndrome, provides a possible explanation for the
discrepant reported data. We show that the degree of
PATCHED1 deficiency is variable among patient cells and
that only severely decreased gene expression correlates
with significantly increased radiosensitivity. Interestingly,
we found that the increased sensitivity also affected cell
response to low radiation doses, which had not been
documented previously. Similarly to Gorlin syndrome, cell
phenotypes from other radiosensitive syndromes are het-
erogeneous. For example, ATM genetic defects range from
complete absence to some persistence of ATM kinase ac-
tivity (29, 30). As a result, not all patients with A-T,
including even homozygotes, are equally radiosensitive,
testifying to the importance of defining target protein levels
and activity for radiosensitive syndromes in each patient.
To demonstrate the link between PATCHED1 and
radiation sensitivity at a molecular level, RNA interference-
mediated PTCH1 deficiency was obtained in primary
fibroblasts from different healthy donors, which systemat-
ically resulted in reduced cell survival after irradiation for
both high and low radiation doses, suggesting that PTCH1
directly regulates cellular radiosensitivity.To assess the underlying mechanisms, the status of DDR
proteins of the ATM/P53 pathways was investigated.
Radiosensitive Gorlin cells showed reduced expression and
activation of proteins from this pathway, varying according
to cell strain but graded according to cell radiosensitivity.
Moreover, genetically induced PTCH1 downregulation in
cells from healthy donors resulted in reduced basal
expression of DDR proteins, close to that found in the
radiosensitive Gorlin cells. It can be hypothesized that
PATCHED1 interacts directly with DDR proteins; this
interaction is currently unverified and would deserve
further studies. Also, a downstream member of the SHH
pathway, affected by PTCH1 deficiency, may impair the
DDR. The GLI family of transcription factors, which are
downstream regulators of SHH (31), are good candidates
for further exploration. In fact, studies in human cancer
cells have shown that inhibition of the activity of GLI
factors can affect cell cycle arrest and DNA repair, as
reviewed by Palle et al (32). Studies on Ptch1 knockout
mouse models also support this hypothesis; for example,
mutant mouse cerebella present a defect in Chek1 activa-
tion mediated by Gli1 after irradiation, leading to a reduced
survival in clonogenic assays (11). The best candidate
might be GLI2; studies in the development of mouse em-
bryos and NIH3T3 fibroblasts show that GLI2 regulation
has a dominant influence on the overall SHH signaling
dynamics (31). The downregulation of GLI2 that we show
in the present study also strengthens this hypothesis.
A B
DC
21381657HNF 3HNF 2HNF 1 1552
Dose (Gy) 0 2 0 2 0 2 0 2 0 2 0 2
DDR protein levels at 2 Gy DDR activation by IR
53BP1 fociγH2AX foci
HN
F 1
HN
F 2
HN
F 3
16
57
15
52
21
38
ATM
CHK2
P53
β-Actin
0 0.25 2 6 24 48 0 0.25 2 6 24 48
Av
er
ag
e 
fo
ci
 n
um
be
r/
ce
ll
Repair time post 3 Gy (h) Repair time post 3 Gy (h)
HNF HNF
Vinculin
p-P53
p-CHK2
p-ATM
Gorlin cells Gorlin cells
Av
er
ag
e 
fo
ci
 n
um
be
r/
ce
ll40
30
20
10
0
80
60
40
20
0
Fig. 2. Impaired DNA damage response (DDR) signaling in radiosensitive Gorlin cells. (A) Reduced expression of 3 DDR
proteins after 2 Gy irradiation (total protein extracts). (B) Defective phosphorylation of ATM, CHK2, and P53 at 1 hour after
2 Gy irradiation. Representative images of Western blot analysis with phospho-ATM (Ser1981), -CHK2 (Ser19), and eP53
(Ser15) antibodies, with vinculin as a loading control of total protein extracts. (C) Comparable average numbers of separate
gH2AX foci in normal and each of 6 Gorlin cell lines, assessed at various times after irradiation on at least 300 cells per
condition. (D) Comparable average numbers of 53BP1 foci in normal and each of 6 Gorlin cell lines at various times,
assessed after irradiation on at least 50 cells per condition.
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damage and repair: PTCH1 defects seemed not to correlate
with impaired double-strand break recognition, as revealed
by the normal findings for gH2AX and 53 BP1 foci
recruitment and kinetics. Based on these data, we propose
that defective cell-cycle checkpoints and replication errors
may be the key impaired processes in Gorlin cells, and this
hypothesis is supported by the CHK2 anomalies consis-
tently found both in patients and after shRNA-mediated
PTCH1 downregulation.
Concerning genetic defects, for 2 radiosensitive patients
with Gorlin syndrome, the mutations found in PTCH1 exon
2 result in stop codons, which explains the observed
decrease in mRNA and protein expression. For one radio-
sensitive patient, the decreased mRNA and protein
expression could not be explained by mutations in the
coding regions of the PTCH1 gene. Several hypotheses can
be suggested for this patient, notably mutations in other
genes, such as those of the GLI family. Epigenetic mech-
anisms might also be involved, such as enhancererelateddownregulation recently described in a case of geno-
dermatosis (33) or inhibition by posttranscriptional regu-
latory networks such as LncRNAs or miRNAs (34, 35).
Databases report several enhancer elements associated with
the PTCH1 gene, including 5 within the gene, and several
long noncoding RNAs, which could all regulate its
expression and deserve further investigation. The fact that
no correlation has yet been demonstrated at the clinical
level between genotypes and phenotypes in patients with
Gorlin syndrome, as mutations in the same region or an
identical mutation in 2 unrelated patients can lead to
different clinical outcomes, supports the likely importance
of epigenetic regulation for the PTCH1 gene.
Clinical consequences for radiation therapy and nuclear
medicine can be extrapolated from the present findings.
According to the Leiden Open Variation Database (36), at
least 14% of patients with Gorlin syndrome with a mutation
in the PTCH1 gene carry this mutation in the first 3 exons,
and thus high gene expression deficiency and radiosensi-
tivity can be expected in these patients, for whom the risk/
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Fig. 3. PATCHED1 deficiency is directly associated with radiosensitivity. (A) PTCH1 messenger RNA levels measured by
quantitative polymerase chain reaction after 3 independent infections of normal fibroblasts (HNF1 and HNF2: 2 healthy donors)
with a lentiviral vector carrying either a short hairpin RNA (shRNA)-scramble sequence or a shRNA targeting PTCH1. Infected
cells were compared with the mean value of the noninfected cells, normalized to 100. (B) Representative image of Western blot
analysis with PATCHED1 antibody (L isoform) for normal fibroblasts (HNF1 and HNF2), either in control conditions or infected
with lentiviral vectors (sh-scramble or sh-PTCH1). (C) Mean survival after 2 Gy was lower in the shRNA-PTCH1 condition than in
the control condition (normalization to 100 vs the noninfected cells) but not in the shRNA-scramble condition; 3 independent
experiments. (D) Mean survival was reduced after a range of radiation doses in sh-PTCH1 infected cells (gray) versus noninfected
cells (HNF1, black), but not in the sh-scramble infected cells (dashed line); 6 flasks per dose, nZ 1. (E) Colony survival assays
showed that cells from healthy donor 1 (HNF1) transduced with sh-PTCH1 lentivector showed a reduced survival after low dose
irradiation, whereas cells receiving control vector did not differ from controls. PZ .0022. (F) Western blot analysis of basal levels
of PATCHED1, CHK2, and P53 after PTCH1 knockdown in normal fibroblasts (HNF4), noninfected or infected with an sh-
scramble or sh-PTCH1 vector (3 independent infections for each); a radiosensitive Gorlin cell strain (GM0-1552) was added
for comparison, and actin was used as a loading control of total protein extracts. Significant at *P < .05 and **P < .01.
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evaluated. Because we found that the increased sensitivity
also affected cell responses to low radiation doses, we
suggest that repeated biomedical diagnostics using x-rays
should also be carefully evaluated for these patients. A
genetic test of blood samples to discriminate such at-risk
patients might be developed and could be included in the
development of systemic next-generation sequencing in the
framework of personalized cancer genomic medicine. This
approach might also be used for other genetic diseases
associated with PTCH1 defects, such as microphthalmia or
Hirschsprung syndrome.
In conclusion, the major finding of the present study is
an inverse correlation PATCHED1 level and cellular
radiosensitivity, affecting both high and low radiation
doses. Furthermore, RNA interference-mediated PTCH1
deficiency in normal human cells resulted in reduced sur-
vival after irradiation, which directly links this gene to
intrinsic radiosensitivity.
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